Structure of Bedaquiline fumarate
CAS No.: 845533-86-0
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Bedaquiline fumarate, a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections.
Synonyms: R403323; TMC207 fumarate; TMC-207
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 845533-86-0 |
Formula : | C36H35BrN2O6 |
M.W : | 671.58 |
SMILES Code : | O[C@](CCN(C)C)(C1=C2C=CC=CC2=CC=C1)[C@@H](C3=CC4=CC(Br)=CC=C4N=C3OC)C5=CC=CC=C5.O=C(O)/C=C/C(O)=O |
Synonyms : |
R403323; TMC207 fumarate; TMC-207
|
MDL No. : | MFCD28167761 |
InChI Key : | ZLVSPMRFRHMMOY-WWCCMVHESA-N |
Pubchem ID : | 24812732 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501 |
In Vitro:
Concentration | Treated Time | Description | References |
Mycobacterium avium | 0.03 and 16 mg/L | Not used | Evaluate the in vitro activity of bedaquiline against nontuberculous mycobacteria, results showed that bedaquiline exhibited the highest activity against Mycobacterium avium | PMC5404590 |
Mycobacterium abscessus | 0.5 μM (MIC) | 48 h | To evaluate the effect of bedaquiline on the bactericidal activity of β-lactams. Results showed that bedaquiline dose-dependently reduced the bactericidal activity of β-lactams. | PMC6658768 |
Mycobacterium abscessus | 0.5 μM (MIC) | 4 h | To determine whether β-lactams cause an increase in intrabacterial ATP and assess the inhibitory effect of bedaquiline on this burst. Results showed that β-lactams induced an ATP burst, which was suppressed by bedaquiline. | PMC6658768 |
Mycobacterium tuberculosis H37Rv | 0.5–1 µg/mL | 14 days | To determine the minimum inhibitory concentration (MIC) of bedaquiline against Mycobacterium tuberculosis H37Rv. Results showed the MIC of bedaquiline was 0.5–1 µg/mL. | PMC10720489 |
Mycobacterium kansasii | 0.016 μg/ml | Evaluate the in vitro activity of Bedaquiline against nontuberculous mycobacteria, showing low MIC values for Mycobacterium kansasii. | PMC6658790 | |
Mycobacterium abscessus subsp. massiliense | 0.062 μg/ml | Evaluate the in vitro activity of Bedaquiline against nontuberculous mycobacteria, showing low MIC values for Mycobacterium abscessus subsp. massiliense. | PMC6658790 | |
Mycobacterium abscessus subsp. abscessus | 0.062 μg/ml | Evaluate the in vitro activity of Bedaquiline against nontuberculous mycobacteria, showing low MIC values for Mycobacterium abscessus subsp. abscessus. | PMC6658790 | |
Mycobacterium intracellulare | 0.016 μg/ml | Evaluate the in vitro activity of Bedaquiline against nontuberculous mycobacteria, showing low MIC values for Mycobacterium intracellulare. | PMC6658790 | |
Mycobacterium avium | 0.016 μg/ml | Evaluate the in vitro activity of Bedaquiline against nontuberculous mycobacteria, showing low MIC values for Mycobacterium avium. | PMC6658790 | |
Mycobacterium tuberculosis mutant CV37 | 0.06–0.0038 mg/L | 4 weeks | To assess the selection advantage of Rv0678 mutants at sub-MIC concentrations, results showed significant enrichment of Rv0678 mutants at sub-MIC concentrations of BDQ and CFZ | PMC10989023 |
Mycobacterium tuberculosis wild-type H37Rv | 0.06–0.0038 mg/L | 4 weeks | To assess the selection advantage of Rv0678 mutants at sub-MIC concentrations, results showed significant enrichment of Rv0678 mutants at sub-MIC concentrations of BDQ and CFZ | PMC10989023 |
Mycobacterium abscessus CIP104536T(S) | 0.125 μg/ml | 4 days | To evaluate the in vitro growth inhibitory effect of bedaquiline on Mycobacterium abscessus, results showed that bedaquiline has a bacteriostatic effect against M. abscessus in vitro. | PMC5655087 |
THP-1 macrophages | 20 µg/ml | 2 days | To evaluate the therapeutic effect of VER and BDQ combination on M. abscessus-infected macrophages, results showed VER significantly enhanced BDQ activity | PMC6709475 |
Mycobacterium abscessus CIP104536T | 64 ng/ml | 4 days | To determine the MIC of BDQ against M. abscessus, results showed VER significantly enhanced BDQ activity | PMC6709475 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
BALB/c mice | Subacute tuberculosis infection model | Oral | 25 mg/kg | 5 days per week for 4 weeks | To evaluate the bactericidal activity of bedaquiline in combination with pretomanid and linezolid in a mouse model of tuberculosis. Results showed that bedaquiline combined with pretomanid and linezolid significantly reduced lung colony-forming unit (CFU) counts. | PMC10720489 |
BALB/c mice | High-dose aerosol infection model of tuberculosis | Oral gavage | 25 mg/kg | Once daily, 5 days per week for 1.5 months | Evaluate the bactericidal and sterilizing activity of Bedaquiline combined with pyrazinamide and moxifloxacin. Results showed that the BZM regimen significantly reduced lung CFU counts after 1 month and significantly decreased relapse rates after 1.5 months of treatment. | PMC9017355 |
Zebrafish | M. abscessus-infected zebrafish embryo model | Water bath administration | 1-3 μg/ml | Daily change of drug-supplemented water for 3 days | To evaluate the therapeutic effect of bedaquiline in a zebrafish model of M. abscessus infection, results showed that bedaquiline significantly increased the survival rate of infected embryos and reduced the formation of abscesses and cords. | PMC5655087 |
C3HeB/FeJ and BALB/c mice | Murine tuberculosis model | Oral | 25 mg/kg | 5 times per week for 4 to 8 weeks | To evaluate the bactericidal and sterilizing activity of the TBI-166, Bedaquiline, and Pyrazinamide combination regimen in murine tuberculosis models. Results showed that the combination regimen achieved culture-negative lungs after 4 weeks of treatment and no relapse after 8 weeks, with superior bactericidal and sterilizing activity compared to the HRZ regimen and TBI-166+BDQ+LZD regimen. | PMC9487531 |
BALB/c mice | Paucibacillary mouse model of latent tuberculosis infection | Intramuscular injection | 160 mg/kg | Monthly for 12 weeks | To evaluate the pharmacokinetics and bactericidal activity of a long-acting injectable bedaquiline formulation in a mouse model of latent tuberculosis infection. Results showed that a single dose of bedaquiline exhibited sustained bactericidal activity for at least 12 weeks. | PMC6437534 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT03625739 | - | Recruiting | December 31, 2026 | China ... More >> Beijing Children's Hospital of Capital Medical University Recruiting Beijing, China Contact: Adong Shen, Master 13370115087 shenad16@hotmail.com Less << | |
NCT03474198 | Tuberculosis, Pulmonary | Phase 2 Phase 3 | Recruiting | March 12, 2022 | Philippines ... More >> De La Salle Health Sciences Institute Not yet recruiting Manila, Philippines Lung Center Philippines Recruiting Manila, Philippines Philippines Tuberculosis Society Incorporated (PTSI) Not yet recruiting Manila, Philippines Tropical Disease Foundation Not yet recruiting Manila, Philippines Singapore National University Hospital Not yet recruiting Singapore, Singapore Thailand King Chulalongkorn Memorial Hospital Not yet recruiting Bangkok, Thailand Less << |
NCT00042289 | HIV Infections | Phase 4 | Recruiting | September 30, 2019 | - |
NCT03237182 | Tuberculosis, Multidrug-Resist... More >>ant Less << | Phase 4 | Recruiting | December 2021 | South Africa ... More >> King Dinuzulu Hospital Recruiting Durban, Kwa-Zulu Natal, South Africa Contact: Nesri Padayatchi, MBcHB 0312604550 nesri.padayatchi@caprisa.org Contact: Resha Boodhram, BTech 0828383651 resha.boodhram@caprisa.org Less << |
NCT02454205 | Tuberculosis ... More >>Multidrug Resistant Tuberculosis Extensively-drug Resistant Tuberculosis Less << | Phase 2 Phase 3 | Recruiting | January 2019 | South Africa ... More >> Brooklyn Chest Hospital Recruiting Cape Town, Western Cape, South Africa, 7441 Contact: Ali Esmail, MD 0214047654 ext 6119 a.esmail@uct.ac.za Contact: Lynelle Mottay, MD 0214046119 ext 6119 lynelle.mottay@uct.ac.za Less << |
NCT02409290 | MDR-TB | Phase 3 | Recruiting | December 2021 | China ... More >> Beijing Chest Hospital Not yet recruiting Beijing, China Wuhan Institute for TB control Not yet recruiting Wuhan, China Ethiopia Armauer Hanssen Research Institute Recruiting Addis Ababa, Ethiopia St. Peter's Tuberculosis Specializes Hospital Recruiting Addis Ababa, Ethiopia Georgia JSC National Center for Tuberculosis and Lung Diseases Recruiting Tbilisi, Georgia India BJ Medical College Civil Hospital Recruiting Ahmedabad, India The National Institute for Research in Tuberculosis Recruiting Chennai, India Indonesia RSUP Persahabatan Not yet recruiting Jakarta, Indonesia Moldova, Republic of Institute of Phthisiopneumology 'Chiril Draganiuc' Recruiting Chisinau, Moldova, Republic of Mongolia National Centre for Communicable Diseases Recruiting Ulaanbaatar, Mongolia South Africa King Dinizulu Hospital Recruiting Durban, South Africa Helen Joseph Hospital Recruiting Johannesburg, South Africa Sizwe Tropical Disease Hospital Active, not recruiting Johannesburg, South Africa Doris Goodwin Hospital Recruiting Pietermaritzburg, South Africa Empilweni TB Hospital Not yet recruiting Port Elizabeth, South Africa Uganda Makerere University Recruiting Kampala, Uganda Mulago National Referral Hospital Recruiting Kampala, Uganda Vietnam Pham Ngoc Thach Hospital Active, not recruiting Ho Chi Minh City, Vietnam Less << |
NCT02754765 | Tuberculosis, Multidrug-Resist... More >>ant Less << | Phase 3 | Recruiting | April 2021 | Georgia ... More >> National Center for Tuberculosis and Lung Diseases Recruiting Tbilisi, Georgia, 0101 Contact: Nino Kiria, MD msff-tbilisi-endtb@paris.msf.org Principal Investigator: Nana Kiria, MD Kazakhstan National Center for Tuberculosis Problems Recruiting Almaty, Kazakhstan Contact: Kanat Khazhidinov, MD kkhazhidinov@pih.org Principal Investigator: Elmira Berikova, MD Kyrgyzstan Osh Oblast Tuberculosis Hospital Not yet recruiting Osh, Kyrgyzstan Contact: Arnol Samiev, MD msfch-osh-tb@geneva.msf.org Principal Investigator: Kauk Galina Vladimirovna, MD Lesotho Partners In Health Lesostho Recruiting Maseru, Lesotho Contact: Sesomo Mohale smohale@pih.org Principal Investigator: Lawrence Oyewusi, MBBS Peru Socios En Salud Recruiting Lima, Peru Contact: Fanny Garcia Velarde fgarcia_ses@pih.org Principal Investigator: Leo Lecca, MD South Africa Medecins Sans Frontieres Belgium Recruiting Khayelitsha, South Africa, 7784 Contact: Jared Borain msfocb-khayelitsha-endtb@brussels.msf.org Principal Investigator: Sean Wasserman, MD Less << |
NCT03259269 | - | Recruiting | September 30, 2020 | Armenia ... More >> National Treatment Centre for Tuberculosis, Abovian, Armenia Recruiting Abovyan, Armenia Contact: Naira Khachatryan, MD msff-erevan-medco@paris.msf.org Principal Investigator: Armen Hayrapetyan, MD Bangladesh National Institute of Diseases of the Chest and Hospital (NIDCH), Dhaka Recruiting Dhaka, Bangladesh Contact: Hamidah Hussain, MBBS, MSc hamidah.hussain@irdresearch.org Contact: Manzur ul-Alam, MD manzur.ulalam@irdresearch.org Belarus Republican Research and Practical Centre for Pulmonology and Tuberculosis Recruiting Minsk, Belarus, 220053 Contact: Yoseph Tassew, MD russia-medco@oca.msf.org Principal Investigator: Alena Skrahina, MD, PhD, DSc Ethiopia Bishoftu Hospital Recruiting Bishoftu, Ethiopia Contact: Andargachew Kumsa, MD AKumsa@pih.org Georgia National Center for Tuberculosis and Lung Diseases Recruiting Tbilisi, Georgia, 0101 Contact: Tinatin Kotrikadze, MD msff-tbilisi-medco@paris.msf.org Principal Investigator: Zara Avaliani, MPH, PhD Indonesia RS Islam Jakarta Cempaka Putih Not yet recruiting Jakarta, Indonesia Contact: Fauziah Asnely Putri, MD, MPH fauziah.putri@irdresearch.org Kazakhstan National Research Center for Phthisionpulmonology Recruiting Almaty, Kazakhstan, 050010 Contact: Yerkebulan Algozhin, MD ealgozhin@pih.org Principal Investigator: Elmira Berikova, MPH Kenya MSF Tuberculosis clinic, Mathare, Nairobi, Kenya Recruiting Nairobi, Kenya Contact: Stephen Wanjala, MD msff-nairobi-medco@paris.msf.org Principal Investigator: Maureen Kamene, MD, MBCHB Kyrgyzstan Kara-Suu District TB hospital Recruiting Kara-Suu, Kyrgyzstan Contact: Hayk Karakozian, MD MSFCH-Kyrgyzstan-Medco@geneva.msf.org Principal Investigator: Kadyrov Abdullaat, MD, PhD Lesotho Botshabelo Hospital Recruiting Maseru, Lesotho Contact: Kwonjune Seung, MD kjseung@pih.org Myanmar Aung San Tuberculosis Hospital Not yet recruiting Yangon, Myanmar Contact: Jarmila Kliescikova, MD myanmar-medco@oca.msf.org Principal Investigator: Si Tu Aung, MD Pakistan The Indus Hospital, Karachi Recruiting Karachi, Pakistan Contact: Rabia Mashkoor, MD rabia.mashkoor@ghd.ihn.org.pk Principal Investigator: Sana Adnan, MBBS, MSPH Institute of Chest Diseases, Kotri Recruiting Kotri, Pakistan Contact: Rabia Mashkoor, MD rabia.mashkoor@ghd.ihn.org.pk Principal Investigator: Sana Adnan, MBBS, MSPH Gulab Devi Chest Hospital, Lahore Recruiting Lahore, Pakistan Contact: Rabia Mashkoor, MD rabia.mashkoor@ghd.ihn.org.pk Principal Investigator: Sana Adnan, MBBS, MSPH Peru Socios en Salud Not yet recruiting Carabayllo, Peru Contact: Carmen Contreras, BS ccontreras_SES@pih.org Principal Investigator: Leonid Lecca, MD South Africa King Dinuzulu Hospital Recruiting Durban, South Africa Contact: Munira Khan, MBCHB munira.khan@irdresearch.org Less << | |
NCT01215851 | Pulmonary Tuberculosis | Phase 2 | Completed | - | South Africa ... More >> Centre for Tuberculosis Research Innovation, UCT Lung Institute Cape Town, South Africa, 7700 Task Applied Science, Karl Bremer Hospital Cape Town, South Africa Less << |
NCT03338621 | Tuberculosis, Pulmonary ... More >> Tuberculosis, Multidrug-Resistant Tuberculosis, MDR Tuberculosis Drug-Resistant Tuberculosis Less << | Phase 2 | Recruiting | January 31, 2022 | Georgia ... More >> National Center for Tuberculosis and Lung Diseases Recruiting Tbilisi, Georgia, 0101 Contact: Marike Eristavi, MD +99 559 954 0393 ma.eristavi@gmail.com Contact: Nestan Tukvadze Less << |
NCT01691534 | Pulmonary Tuberculosis | Phase 2 | Completed | - | South Africa ... More >> Centre for Tuberculosis Research Innovation, UCT Lung Institute Cape Town, South Africa Task Applied Science, Karl Bremer Hospita Cape Town, South Africa Less << |
NCT01691534 | - | Completed | - | - | |
NCT02589782 | Tuberculosis, Multidrug-Resist... More >>ant Extensively Drug-Resistant Tuberculosis Tuberculosis, Pulmonary Less << | Phase 2 Phase 3 | Recruiting | March 2021 | Belarus ... More >> Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital Recruiting Minsk, Belarus Contact: Animesh Sinha, MD minsk-ct-mtl@oca.msf.org Principal Investigator: Alena Skrahina, MD South Africa Doris Goodwin Hospital Recruiting Pietermaritzburg, KwaZulu Natal, South Africa Contact: Suzanne Staples s.staples@thinksa.org.za Principal Investigator: Ronelle Moodliar, MBBS, MMed Don McKenzie Hospital Not yet recruiting Durban, KwaZulu-Natal, South Africa Contact: Suzanne Staples s.staples@thinksa.org.za Principal Investigator: Ronelle Moodliar, MBBS,MMed Uzbekistan Republican TB Hospital No. 2 Recruiting Nukus, Karakalpakstan, Uzbekistan Contact: Timur Gilmanov NukusCT-crc@oca.msf.org Principal Investigator: Tigay N Zinaida, MD Sh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital Not yet recruiting Tashkent, Uzbekistan Contact: Viktoria Prymaka Principal Investigator: Irina Liverko, MD Less << |
NCT03086486 | Tuberculosis, Pulmonary ... More >> Tuberculosis, Multidrug-Resistant Tuberculosis, MDR Tuberculosis Extensively Drug-Resistant Tuberculosis Pre-XDR-TB Less << | Phase 3 | Recruiting | January 2022 | Georgia ... More >> National Center for Tuberculosis and Lung Diseases Recruiting Tbilisi, Georgia, 0101 Contact: Lali Mikiashvili Principal Investigator: Lali Mikiashvili Moldova, Republic of Institute of Phthisiopneumology Chiril Draganiuc Not yet recruiting Chisinau, Moldova, Republic of, 2025 Contact: Elena Tudor, MD Principal Investigator: Elena Tudor, MD Russian Federation Central TB Research Institute of the Federal Agency of Scientific Organizations Moscow Not yet recruiting Moscow, Russian Federation, 107564 Contact: Tatevik Bagdasaryan Principal Investigator: Tatevik Bagdasaryan Research Institute of Phthisiopulmonology of I.M. Sechenov First Moscow State Medical University Not yet recruiting Moscow, Russian Federation Contact: Anastasia Samoilova Principal Investigator: Anastasia Samoilova FSBI "Saint-Petersburg Research Institute of Phthisiopulmonology" Recruiting Saint Petersburg, Russian Federation, 191036 Contact: Petr Yablonskiy, MD Principal Investigator: Petr Yablonskiy, MD Ural Research Institute of Phthisiopulmonology Not yet recruiting Yekaterinburg, Russian Federation, 620039 Contact: Sergey Skornyakov, MD Principal Investigator: Sergey Skornyakov, MD South Africa Tshepong Hospital Recruiting Klerksdorp, North - West, South Africa, 2574 Contact: Ebrahim Variava Principal Investigator: Ebrahim Variava King DinuZulu Hospital Complex Recruiting Durban, South Africa, 4015 Contact: Nosipho Ngubane Principal Investigator: Nosipho Ngubane Clinical HIV Research Unit (CHRU) Sizwe Tropical Diseases Hospital Recruiting Johannesburg, South Africa, 2131 Contact: Pauline Howell, MD Principal Investigator: Pauline Howell, MD Empilweni TB Hospital Not yet recruiting Johannesburg, South Africa, 2194 Contact: Francesca Conradie, MBBS Principal Investigator: Francesca Conradie, MBBS Less << |
NCT01215851 | - | Completed | - | - | |
NCT01600963 | Multi-drug Resistant Tuberculo... More >>sis Less << | Phase 3 | Withdrawn(PhIII program revise... More >>d; TMC207-C210 cancelled) Less << | November 2022 | - |
NCT00946842 | Healthy | Phase 1 | Completed | - | - |
NCT02193776 | Tuberculosis | Phase 2 | Completed | - | South Africa ... More >> The Aurum Institute: Tembisa Hospital Tembisa, Gauteng, South Africa, 1632 Klerksdorp Tshepong Hospital Jouberton, Klerksdorp, South Africa, 2570 TASK Applied Science Cape Town, South Africa, 7531 University of Cape Town Lung Institute (Pty) Ltd Cape Town, South Africa, 7937 THINK: Tuberculosis & HIV Investigative Network of KwaZulu-Natal Durban, South Africa CHRU Themba Lethu Clinic Johannesburg, South Africa University of Witwatersrand, Clinical HIV Research Unit (CHRU), Helen Joseph Hospital Johannesburg, South Africa Tanzania Ifakara Health Institute Bagamoyo, Tanzania NIMR-Mbeya Medical Research Centre (MMRC) Mbeya, Tanzania Uganda Uganda Case Western Reserve University Research Collaboration Kampala, Uganda Less << |
NCT00449644 | - | Completed | - | - | |
NCT02583048 | Tuberculosis ... More >>HIV Infections Less << | Phase 2 | Active, not recruiting | April 27, 2020 | Peru ... More >> Barranco CRS Lima, Peru, 15063 South Africa Task Applied Science (TASK) CRS Cape Town, Western Cape Province, South Africa, 7530 South African Tuberculosis Vaccine Initiative (SATVI) CRS Cape Town, Western Cape Province, South Africa, 7705 Less << |
NCT01464762 | - | - | - | Lithuania ... More >> Vilnius, Lithuania Russian Federation Arkhangelsk, Russian Federation Moscow, Russian Federation Orel, Russian Federation Saint-Petersburg, Russian Federation Less << | |
NCT00449644 | Tuberculosis | Phase 2 | Completed | - | Brazil ... More >> Rio De Janeiro, Brazil India Chennai, India New Delhi, India Latvia Stopinu Region, Latvia Peru Lima, Peru Philippines Quezon City, Philippines Russian Federation Moscow, Russian Federation South Africa Bethelsdorp, South Africa Cape Town, South Africa Durban, South Africa George, South Africa Klerksdorp, South Africa Sandringham, South Africa Thailand Chiang Mai, Thailand Nakhon, Thailand Nonthaburi, Thailand Less << |
NCT01341184 | Tuberculosis | Phase 1 | Completed | - | United States, Ohio ... More >> Case Western Reserve University - Case Medical Center - Infectious Disease & HIV Medicine Cleveland, Ohio, United States, 44106-1716 Less << |
NCT01291563 | Healthy Volunteer | Phase 1 | Completed | - | - |
NCT01215110 | Pulmonary Tuberculosis | Phase 2 | Completed | - | South Africa ... More >> Karl Bremer Hospital Belville, Cape Town, South Africa, 7531 Less << |
NCT02274389 | - | Active, not recruiting | December 31, 2018 | United States, North Carolina ... More >> Raleigh, North Carolina, United States Less << | |
NCT00523926 | Tuberculosis | Phase 2 | Completed | - | - |
NCT00992069 | Tuberculosis ... More >>HIV Less << | Phase 1 | Completed | - | United States, California ... More >> Ucsf Aids Crs San Francisco, California, United States, 94110 United States, Maryland Johns Hopkins Adult AIDS CRS Baltimore, Maryland, United States, 21287 United States, North Carolina Unc Aids Crs Chapel Hill, North Carolina, United States, 27514 United States, Ohio The Ohio State Univ. AIDS CRS Columbus, Ohio, United States, 43210 United States, Tennessee Vanderbilt Therapeutics CRS Nashville, Tennessee, United States, 37232-2582 Less << |
NCT02333799 | Pulmonary Tuberculosis | Phase 3 | Active, not recruiting | October 2021 | South Africa ... More >> Task Applied Science - Brooklyn Chest Hospital Ysterplaat, Cape Town, South Africa, 7405 King DinuZulu Hospital Complex Sydenham, Durban, South Africa, 4001 Sizwe Tropical Disease Hospital Sandringham, Johannesburg, South Africa, 2131 THINK: Tuberculosis & HIV Investigative Network of KwaZulu-Natal (Durban) Pietermaritzburg, Kwazulu-Natal, South Africa, 3200 Less << |
NCT02906007 | Tuberculosis ... More >>HIV Infections Less << | Phase 1 Phase 2 | Recruiting | January 31, 2022 | Haiti ... More >> Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS Recruiting Port-au-Prince, Haiti, HT-6110 Contact: Cynthia Riviere, M.D. 509-22222241 criviere@gheskio.org India Byramjee Jeejeebhoy Medical College (BJMC) CRS Recruiting Pune, Maharashtra, India, 411001 Contact: Nishi Suryavanshi, Ph.D. 91-98-23248979 nishi@jhumitpune.com South Africa Sizwe CRS Recruiting Johannesburg, Gauteng, South Africa Contact: Katerina Selibas 27-11-8823912 kselibas@witshealth.co.za PHRU Matlosana CRS Recruiting Klerksdorp, North West Province, South Africa, 2574 Contact: Katlego Motlhaoleng 27-18-4063359 motlhaolengk@phru.co.za Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS Recruiting Cape Town, Western Cape Province, South Africa, 7505 Contact: Frieda A. Verheye-Dua 27-21-9389772 Frieda@sun.ac.za Less << |
NCT00910806 | HIV Infections | Phase 1 | Completed | - | South Africa ... More >> George, South Africa Less << |
NCT00828529 | Tuberculosis ... More >>HIV Less << | Phase 1 | Completed | - | - |
NCT00910871 | Tuberculosis | Phase 2 | Completed | - | - |
NCT01012284 | Moderate Hepatic Impairment | Phase 1 | Completed | - | - |
NCT00910871 | - | Completed | - | - | |
NCT03032367 | Tuberculosis | Early Phase 1 | Completed | - | South Africa ... More >> TASK Clinical Research Centre Bellville, Western Cape, South Africa, 7530 Less << |
NCT02216331 | Tuberculosis | Phase 1 | Completed | - | United States, Nebraska ... More >> Celerion (MDS Pharma Services) Lincoln, Nebraska, United States, 68502 Less << |
NCT01803373 | Healthy Biolo... More >>gical Availability Less << | Phase 1 | Completed | - | Netherlands ... More >> Groningen, Netherlands Less << |
NCT02365623 | Tuberculosis, Multidrug-Resist... More >>ant Less << | Phase 2 | Active, not recruiting | September 12, 2020 | Japan ... More >> Kiyose, Japan Sakai, Japan Less << |
NCT03384641 | Leprosy, Multibacillary | Phase 2 | Recruiting | July 7, 2021 | Brazil ... More >> Instituto Lauro de Souza Lima Recruiting Bauru, Brazil, 17034-971 Alfredo da Matta Foundation Not yet recruiting Manaus, Brazil, 69065-130 Less << |
NCT02354014 | Multidrug-Resistant Tuberculos... More >>is Less << | Phase 2 | Recruiting | July 13, 2025 | India ... More >> B. J. Medical College & Civil Hospital Withdrawn Ahmedabad, India, 380 016 National Institute for Research in Tuberculosis (NIRT) Withdrawn Chennai, India, 600 031 National Institute of Tuberculosis and Respiratory Diseases (NITRD) Withdrawn New Delhi, India, 110 030 Philippines De La Salle Health Sciences Institute- DLSUMC Recruiting Dasmarinas, Philippines, 4114 Lung Center Of The Philippines Completed Quezon City, Philippines, 1100 Russian Federation First Moscow State Medical University n.a. I.M. Sechenov Recruiting Moscow, Russian Federation, 119991 South Africa THINK: Tuberculosis & HIV Investigative Network Recruiting Durban, South Africa, 4001 Less << |
NCT01215110 | - | Completed | - | - |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.49mL 0.30mL 0.15mL |
7.45mL 1.49mL 0.74mL |
14.89mL 2.98mL 1.49mL |